Verastem Oncology

Verastem Oncology is a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of patients with cancer. The company's pipeline targets the RAS/MAPK signaling pathway, which drives cell survival and tumor growth, through novel small molecule inhibitors. This includes KRAS G12D inhibition, RAF/MEK inhibition, and FAK inhibition to address resistance mechanisms. Verastem achieved an FDA-approved treatment (AVMAPKI FAKZYNJA CO-PACK) for KRAS-mutant recurrent low-grade serous ovarian cancer, the first approved therapy for this indication. The company trades on NASDAQ under the symbol VSTM.